{"title":"什么是前列腺癌的“进展”?","authors":"D W Newling","doi":"10.1002/pros.2990210522","DOIUrl":null,"url":null,"abstract":"If progression can be defined at an early stage, a change in treatment may significantly improve the length and quality of apatient's survival. In this seminar, involving 35 participants, the assessment of progression in phase I1 and phase 111 studies was discussed, against the background of papers prepared by the invited participants, and an analysis of progression in a recent EORTC phase 111 study prepared by Dr. Sylvester.","PeriodicalId":77436,"journal":{"name":"The Prostate. Supplement","volume":"4 ","pages":"139-43"},"PeriodicalIF":0.0000,"publicationDate":"1992-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/pros.2990210522","citationCount":"17","resultStr":"{\"title\":\"What is 'progression' in prostate cancer?\",\"authors\":\"D W Newling\",\"doi\":\"10.1002/pros.2990210522\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"If progression can be defined at an early stage, a change in treatment may significantly improve the length and quality of apatient's survival. In this seminar, involving 35 participants, the assessment of progression in phase I1 and phase 111 studies was discussed, against the background of papers prepared by the invited participants, and an analysis of progression in a recent EORTC phase 111 study prepared by Dr. Sylvester.\",\"PeriodicalId\":77436,\"journal\":{\"name\":\"The Prostate. Supplement\",\"volume\":\"4 \",\"pages\":\"139-43\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1992-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/pros.2990210522\",\"citationCount\":\"17\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Prostate. Supplement\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1002/pros.2990210522\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Prostate. Supplement","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1002/pros.2990210522","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
If progression can be defined at an early stage, a change in treatment may significantly improve the length and quality of apatient's survival. In this seminar, involving 35 participants, the assessment of progression in phase I1 and phase 111 studies was discussed, against the background of papers prepared by the invited participants, and an analysis of progression in a recent EORTC phase 111 study prepared by Dr. Sylvester.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
